Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest - 2Deadly heat worldwide prompts $300 million for climate health research at COP30
- 3Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- 4The most effective method to Go with Informed Choices on Vehicle Leases
- 5Best Amusement Park Bite: What Do You Very much want to Crunch On?
- The most effective method to Beat Dental Tension and Guarantee Customary Exams
- Idris Elba is the king of the stress-watch
- Instructions to Expand Your Smash 1500's Presentation: Tips and Deceives
- Senior's Manual for Obtaining a Hyundai Ioniq EV: Tips
- What's the Fate of 5G Innovation?
- Heart disease risk greater for women with a common condition they may not be aware they have
- German Cabinet advances bill to cut greenhouse emissions from fuels
- The Most Paramount Crossroads in Olympic History
- Geminid shooting stars: One of 2025's most exciting meteor showers begins tonight
